Molecular Nuclear Therapy (MNT) is an innovation combining two approaches: tumor targeting and radiation. Unlike traditional chemotherapy drugs, which do not differentiate between cancerous and healthy cells, MNT selectively targets cancer cells, which can lead to more precise and effective treatment with minimal side effects.
Peptide Receptor Radionuclide Therapy (PRRT) is a form of molecular targeted therapy which involves the systemic administration of a radiopharmaceutical composed of a small targeting protein or peptide that is coupled with a radioisotope or radionuclide emitting beta radiation. The peptide-radionuclide complex, also known as a radiopeptide, is injected into the patient’s bloodstream and binds to specific receptors expressed on the tumor cell’s surface. The radiopeptide is then internalized into the tumor cell, delivering small doses of cancer-killing radiation. Commonly used radionuclides are lutetium 177 (Lu-177) and yttrium 90 (Y-90), selected for their relatively short tissue penetration, which results in direct impact to tumors with minimal ancillary damage to surrounding tissues.